Table 3 Adverse events: overall summary (safety-analysis set)
|  | Eliapixant 25 mg BID n = 39 (100%) | Eliapixant 75 mg BID n = 38 (100%) | Eliapixant 150 mg BID n = 38 (100%) | Placebo n = 37 (100%) | Elagolix 150 mg QD n = 38 (100%) |
|---|---|---|---|---|---|
Any AE | 33 (84.6%) | 28 (73.7%) | 32 (84.2%) | 30 (81.1%) | 32 (84.2%) |
Any SAE | 1 (2.6%) | 2 (5.3%) | 3 (7.9%) | 1 (2.7%) | 2 (5.3%) |
Any AE resulting in death | 0 | 0 | 0 | 0 | 0 |
Any AE resulting in permanent discontinuation of the study drug | 0 | 1 (2.6%) | 1 (2.6%) | 2 (5.4%) | 1 (2.6%) |
Any TEAE | 23 (59.0%) | 21 (55.3%) | 29 (76.3%) | 27 (73.0%) | 28 (73.7%) |
Any drug-related TEAE | 4 (10.3%) | 6 (15.8%) | 10 (26.3%) | 10 (27.0%) | 13 (34.2%) |
Any serious TEAE | 0 | 2 (5.3%) | 2 (5.3%) | 1 (2.7%) | 1 (2.6%) |
Any drug-related serious TEAE | 0 | 0 | 1 (2.6%) | 0 | 1 (2.6%) |
Any TEAE resulting in death | 0 | 0 | 0 | 0 | 0 |
Any TEAE resulting in permanent discontinuation of the study drug | 0 | 1 (2.6%) | 1 (2.6%) | 2 (5.4%) | 1 (2.6%) |